Two cloned macaques named Zhong Zhong and Hua Hua at the non-human-primate research facility under the Chinese Academy of Sciences (CAS). Photo: Xinhua / Jin Liwang via Getty Images

Two biotechnology stories from China captured the world’s attention this past week:

  • First, the WSJ reported that a group of doctors in Hangzhou have been using CRISPR gene-editing in experiments with cancer patients. Elsewhere, medical scientists are far more cautious about using the technology in humans.

The concern: Clinical trials are not always well regulated around the world. The gene editing activity in China not only flouts the safety-first standard in developed countries and exploits desperate patients, it misses an opportunity to learn from carefully designed clinical trials.

  • Second, more than two decades after Dolly the sheep was cloned, scientists in China reported they had cloned the first primate. It required new techniques and involved dozens of failures before two infant monkeys were finally born with perfect copies of the genes in their cells, creating enormous opportunities for comparative research.

What it means: These results reinforce the possibility of using human clones for research. Still, the risks involved in cloning for human reproduction are simply too great, as the many failed attempts at monkey cloning make clear.

The bottom line: These developments are a reminder that the U.S. is no longer the sole player. However, science is not a zero-sum game. Along with the need for appropriate regulation, the question now is whether the U.S. is in a position to collaborate and contribute new information. In that sense, the less flashy National Institutes of Health announcement of a $190 million commitment to support work on new tools for gene editing is ultimately the bigger news this week.

Jonathan D. Moreno is the David and Lyn Silfen University Professor of Ethics at the University of Pennsylvania.

Go deeper

How small businesses got stiffed by the coronavirus pandemic

Illustration: Aïda Amer/Axios

The story of American businesses in the coronavirus pandemic is a tale of two markets — one made up of tech firms and online retailers as winners awash in capital, and another of brick-and-mortar mom-and-pop shops that is collapsing.

Why it matters: The coronavirus pandemic has created an environment where losing industries like traditional retail and hospitality as well as a sizable portion of firms owned by women, immigrants and people of color are wiped out and may be gone for good.

Apple's antitrust fight turns Epic

Illustration: Aïda Amer/Axios

Millions of angry gamers may soon join the chorus of voices calling for an antitrust crackdown on Apple, as the iPhone giant faces a new lawsuit and PR blitz from Epic Games, maker of mega-hit Fortnite.

Why it matters: Apple is one of several Big Tech firms accused of violating the spirit, if not the letter, of antitrust law. A high-profile lawsuit could become a roadmap for either building a case against tech titans under existing antitrust laws or writing new ones better suited to the digital economy.

Survey: Fears grow about Social Security’s future

Data: AARP survey of 1,441 U.S. adults conducted July 14–27, 2020 a ±3.4% margin of error at the 95% confidence level; Chart: Naema Ahmed/Axios

Younger Americans are increasingly concerned that Social Security won't be enough to wholly fall back on once they retire, according to a survey conducted by AARP — in honor of today's 85th anniversary of the program — given first to Axios.

Why it matters: Young people's concerns about financial insecurity once they're on a restricted income are rising — and that generation is worried the program, which currently pays out to 65 million beneficiaries, won't be enough to sustain them.